Business Standard

Pfizer says its booster shot is 95.6% effective against symptomatic Covid

Regulators have wrestled with how widely to use boosters as the fast-spreading delta variant drives infection rates up

Pfizer Vaccine, Coronavirus vaccine
Premium

The trial results show that “booster vaccinations could play an important role in sustaining pandemic containment and a return to normalcy,” BioNTech CEO Ugur Sahin said.

Naomi Kresge | Bloomberg
Pfizer Inc. and BioNTech SE said a booster shot of their Covid-19 vaccine restored full protection in a large study, results that are likely to bolster the argument for giving a third dose more widely.
 
A booster was 95.6% effective against symptomatic Covid in the study, which followed 10,000 people aged 16 and older, the companies said on Thursday. 

Pfizer shares were 0.9% higher in premarket U.S. trading, with BioNTech gaining 1.3% in Frankfurt.

“We believe boosters have a critical role to play in addressing the ongoing public health threat of this pandemic,” Pfizer Chief Executive Officer Albert Bourla said in a

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Oct 21 2021 | 4:59 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com